[Emoxipin pharmacokinetics in normal conditions and in models of experimental pathology].
The experimentally induced infarct and postoperative stress were shown to alter the kinetics of emoxipine consumption revealed in the increase of drug level in the blood. Elimination rate declines resulting in the increase of emoxipine bioavailability. This tendency is especially appreciable during elimination. The high emoxipine concentration appears to be the result of feedback regulation of its delivery from depot. Therefore pathological conditions have a significant effect on pharmacokinetics of emoxipine; this phenomenon seems to intensify the pharmacological action of this drug.
Mishina
E V
EV
Filippenko
N G
NG
Pichugin
V V
VV
Zherdev
V P
VP
Lebedev
A V
AV
Kameneva
N V
NV
Shvedova
A A
AA
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000975:Antioxidants / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001682:Biological Availability; D007262:Infusions, Intravenous; D009203:Myocardial Infarction / Q000188:drug therapy*; D010847:Picolines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011619:Psychotropic Drugs / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011817:Rabbits; D013312:Stress, Physiological / Q000188:drug therapy*
D000889:Anti-Arrhythmia Agents; D000975:Antioxidants; D010847:Picolines; D011619:Psychotropic Drugs; C009820:6-methyl-2-ethyl-3-hydroxypyridine
Farmakokinetika émoksipina v norme i na modeliiakh ksperimental'noĭ patologii.